Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR001 in Relapsed/Refractory CD19+ DLBCL and FL
NCT03720457Phase 1Unknown
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DASH CD19 CAR-T in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Occurrence of study related adverse effects defined by NCI CTCAE 5.0 at 2 years. Status: unknown.
02
Drugs
DASH CD19 CAR-T
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03720457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720457.